scholarly article | Q13442814 |
P356 | DOI | 10.1124/JPET.108.143990 |
P8608 | Fatcat ID | release_3ovrgedbrfc5hoepyuqcwlwzlu |
P932 | PMC publication ID | 2666962 |
P698 | PubMed publication ID | 18812493 |
P5875 | ResearchGate publication ID | 23277525 |
P2093 | author name string | Bojana Zupan | |
Miklos Toth | |||
P2860 | cites work | Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice | Q28504725 |
The mGluR theory of fragile X mental retardation | Q29615060 | ||
Wild-type male offspring of fmr-1+/- mothers exhibit characteristics of the fragile X phenotype | Q30480496 | ||
Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research | Q30676289 | ||
Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila | Q33323032 | ||
Advances in research on the fragile X syndrome | Q33971586 | ||
Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome | Q33990232 | ||
Tonic GABA-ergic modulation of striatal dopamine release studied by in vivo microdialysis in the freely moving rat. | Q34370166 | ||
Neurodevelopmental sequelae of postnatal maternal care in rodents: clinical and research implications of molecular insights | Q36758626 | ||
The GABAA receptor: a novel target for treatment of fragile X? | Q36859341 | ||
The functional output of the mesolimbic dopamine system | Q39548090 | ||
Epilepsy, hyperalgesia, impaired memory, and loss of pre- and postsynaptic GABA(B) responses in mice lacking GABA(B(1)). | Q39576197 | ||
Correlates of maternal behaviours in mothers of children with fragile X syndrome | Q40214386 | ||
Regulation of somatodendritic dopamine release in the ventral tegmental area by opioids and GABA: an in vivo microdialysis study | Q41084585 | ||
Pharmacokinetics of a single oral dose of baclofen in pediatric patients with gastroesophageal reflux disease | Q42693507 | ||
GABA(B) receptor modulators potentiate baclofen-induced depression of dopamine neuron activity in the rat ventral tegmental area | Q43261524 | ||
Fragile X mice develop sensory hyperreactivity to auditory stimuli | Q43574481 | ||
GABA(B) receptor inhibition causes locomotor stimulation in mice | Q43832358 | ||
GABA(B) receptor-mediated modulation of the firing pattern of ventral tegmental area dopamine neurons in vivo | Q43908487 | ||
Bi-directional effects of GABA(B) receptor agonists on the mesolimbic dopamine system | Q44743799 | ||
Nigral GABAergic inhibition upon mesencephalic dopaminergic cell groups in rats | Q44884771 | ||
Mood and anxiety disorders in females with the FMR1 premutation | Q45582526 | ||
(Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features | Q45866804 | ||
A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state. | Q46564236 | ||
RGS2 modulates coupling between GABAB receptors and GIRK channels in dopamine neurons of the ventral tegmental area. | Q46927228 | ||
Opposite changes in the mesolimbic dopamine metabolism in the nerve terminal and cell body sites induced by locally infused baclofen in the rat. | Q48175690 | ||
Suppression of ethanol-induced locomotor stimulation by GABA-like drugs | Q48343565 | ||
Gamma-hydroxybutyrate is a GABAB receptor agonist that increases a potassium conductance in rat ventral tegmental dopamine neurons | Q48379449 | ||
Fmrp is required for the establishment of the startle response during the critical period of auditory development. | Q48455738 | ||
Mildly impaired water maze performance in male Fmr1 knockout mice | Q48818692 | ||
Parenting in mothers with and without attention-deficit/hyperactivity disorder. | Q52025413 | ||
Presynaptic modulation by dopamine and GABA opens a potassium channel in rat cortical, striatal and hippocampal synaptosomes via eicosanoids. | Q54023201 | ||
A controlled trial of stimulant medication in children with the fragile X syndrome | Q70218973 | ||
Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium | Q72065437 | ||
Asymmetric neural control systems in human self-regulation | Q72603210 | ||
GABAB-receptor activation alters the firing pattern of dopamine neurons in the rat substantia nigra | Q72700454 | ||
GABA(B) receptors: altered coupling to G-proteins in rats sensitized to amphetamine | Q73163695 | ||
Case study: maternal residual attention deficit disorder associated with failure to thrive in a two-month-old infant | Q93868741 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 820-826 | |
P577 | publication date | 2008-09-23 | |
P1433 | published in | Journal of Pharmacology and Experimental Therapeutics | Q1500272 |
P1476 | title | Inactivation of the maternal fragile X gene results in sensitization of GABAB receptor function in the offspring | |
P478 | volume | 327 |
Q42959792 | Chemistry and pharmacology of GABAB receptor ligands |
Q41497643 | Dopamine Release and Uptake Impairments and Behavioral Alterations Observed in Mice that Model Fragile X Mental Retardation Syndrome |
Q34198650 | Fragile X and autism: Intertwined at the molecular level leading to targeted treatments |
Q28235219 | KCNQ1, KCNE2, and Na+-coupled solute transporters form reciprocally regulating complexes that affect neuronal excitability |
Q30475378 | Maternal genetic mutations as gestational and early life influences in producing psychiatric disease-like phenotypes in mice |
Q35188148 | Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome |
Q27023257 | Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes |
Q34213731 | The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome |
Q38046662 | mGluR antagonists and GABA agonists as novel pharmacological agents for the treatment of autism spectrum disorders |
Search more.